Ameet Mallik joined ADC Therapeutics in May 2022 and has over 25 years of industry experience. Before joining ADC Therapeutics, he served as CEO of Rafael Holdings, a novel cancer and immune metabolism therapeutics company.
Prior to Rafael Holdings, Mr. Mallik spent more than 16 years at Novartis where he served as Executive Vice President and Head, U.S. Oncology from November 2017 through April 2021. Prior to this position, Mr. Mallik served Novartis Oncology as Global Head, Marketing, Value and Access, and Head, Latin America and Canada. Mr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial and leadership roles at Novartis and Sandoz. At Sandoz, Mr. Mallik was Global Head of Biopharmaceuticals & Oncology Injectables. Before working in pharma, Mr. Mallik was an Associate Principal at McKinsey & Company. He currently serves on the boards of directors of ADC Therapeutics and Atara Biotherapeutics.
Mr. Mallik holds an MBA from the Wharton School at the University of Pennsylvania and an MS in Biotechnology and BS in Chemical Engineering, both from Northwestern University.